

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C

	Simeprevir (Galexos®) 150 mg daily with food	Sofosbuvir (Sovaldi®) 400 mg daily	Sofosbuvir/Ledipasvir (Harvoni®) 400 mg/90 mg coformulation once daily	Daclatasvir (Daklinza®, DCV, BMS-790052) 60 mg daily (licensed in Japan & EU)	Holkira Pak®/Viekira Pak® (US) (Abbvie 3D regimen: paritaprevir/ritonavir, ombitasvir 150/100/25 mg QD plus dasabuvir 250 mg BID)	Grazoprevir (MK-5172) 100 mg/50 mg coformulation once daily (investigational)	Elbasvir (MK-8742)
PIs: atazanavir	Not recommended with ritonavir- or cobicistat boosted PIs (significant ↑ simeprevir AUC). ^{1,2}	OK ³	Potential for ↑ tenofovir concentrations when administered with concomitant booster. Monitor for toxicity. ⁴⁻⁶	↓ daclatasvir dose to 30 mg daily with atazanavir/ritonavir or atazanavir/cobicistat. ^{7,8}	OK with atazanavir 300 mg QD. ^{9,10}	Not recommended with atazanavir/ritonavir (10.58-fold ↑ MK-5172 AUC). ¹¹	Atazanavir concentrations OK, but significant ↑ MK-8742 exposures (4.76-fold). ¹²
PIs: other				No dose modifications required with darunavir/ritonavir, darunavir/cobicistat or lopinavir/ritonavir. ⁸	Darunavir: take without additional ritonavir; monitor HIV viral load due to decreased darunavir Ctrough (Canadian monograph). US monograph: Not recommended due to potential for decreased darunavir Ctrough. ¹⁰ Not recommended with lopinavir/ritonavir due to higher GI side effects and ↑ paritaprevir exposures. ¹³		
NNRTIs	Not recommended with efavirenz or nevirapine (71% ↓ simeprevir AUC). ^{1,2}	Efavirenz OK ³	Efavirenz OK. ¹⁴	↑ daclatasvir dose to 90 mg once daily with efavirenz. ⁷	Contraindicated with efavirenz (increased risk of adverse events including LFT elevations). ^{10,15}	Avoid efavirenz (84% ↓ MK-5172 AUC). ¹⁶	Avoid efavirenz (54% ↓ MK-8742 AUC). ¹⁷
	Not recommended with etravirine. ²			No data. Coadministration not recommended with			

	Simeprevir (Galexos®) 150 mg daily with food	Sofosbuvir (Sovaldi®) 400 mg daily	Sofosbuvir/Ledipasvir (Harvoni®) 400 mg/90 mg coformulation once daily	Daclatasvir (Daklinza®, DCV, BMS-790052) 60 mg daily (licensed in Japan & EU)	Holkira Pak®/Viekira Pak® (US) (Abbvie 3D regimen: paritaprevir/ritonavir, ombitasvir 150/100/25 mg QD plus dasabuvir 250 mg BID)	Grazoprevir (MK-5172) 100 mg/50 mg coformulation once daily (investigational)	Elbasvir (MK-8742)
				etravirine or nevirapine due to potential for ↓ daclatasvir. ¹⁸	3D exposures. ¹⁰		
	Rilpivirine OK. ¹⁹	Rilpivirine OK ³	Rilpivirine OK. ¹⁴	Rilpivirine OK. ^{18, 20}	Not recommended with rilpivirine (116-273% ↑ rilpivirine exposures). ¹⁵	Rilpivirine OK. ²¹	Rilpivirine OK. ²¹
InSTIs			Dolutegravir OK. Monitor for tenofovir-associated toxicities if using tenofovir-based backbone. ²²	Dolutegravir OK. ^{18, 23}	Dolutegravir OK. ²⁴		Dolutegravir OK. ²⁵
	Raltegravir OK. ¹⁹	Raltegravir OK ³	Raltegravir OK. ¹⁴	Raltegravir OK. ²⁰	Raltegravir OK. ^{10, 15}	Raltegravir OK. ²⁶	Raltegravir OK. ¹⁷
	Not recommended with cobicistat-boosted regimens. ¹		Potential for ↑ tenofovir concentrations when administered with concomitant booster. Monitor for toxicity. ^{5, 6} NB: US monograph: combination not recommended. ⁴ Elvitegravir/cobicistat/FTC/tenofovir alafenamide: OK. ²²	↓ daclatasvir dose to 30 mg daily with cobicistat ¹⁸			
Maraviroc				Standard doses of both OK. ¹⁸			
NRTIs	Tenofovir OK. ¹	Tenofovir OK ³	Tenofovir OK. ¹⁴	Tenofovir OK. ⁷	Tenofovir OK. ^{9, 10}	Tenofovir OK. ²⁵	Tenofovir OK. ¹⁷

	Simeprevir (Galexos®) 150 mg daily with food	Sofosbuvir (Sovaldi®) 400 mg daily	Sofosbuvir/ Ledipasvir (Harvoni®) 400 mg/90 mg coformulation once daily	Daclatasvir (Daklinza®, DCV, BMS-790052) 60 mg daily (licensed in Japan & EU)	Holkira Pak®/ Viekira Pak® (US) (Abbvie 3D regimen: paritaprevir/ ritonavir, ombitasvir 150/100/25 mg QD plus dasabuvir 250 mg BID)	Grazoprevir (MK-5172) 100 mg/50 mg coformulation once daily (investigational)	Elbasvir (MK-8742)
			Potential for ↑ tenofovir concentrations when administered with concomitant booster. Monitor for toxicity. ⁶				

Key: = avoid combination = caution/dose adjustment = combination OK

References:

- Ouwerkerk-Mahadevan S, Simion A, Peeters M, et al. Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus NS3/4A protease inhibitor [abstract PE 10/7]. 14th European AIDS Conference (EACS), October 16-19, 2013, Brussels, Belgium.
- Janssen Inc. Galexos (simeprevir) Product Monograph. Toronto, ON November 18, 2013.
- Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers [abstract 1877]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston, MA.
- Gilead Sciences Inc. Harvoni (ledipasvir/sofosbuvir) Product Monograph. Foster City, CA October, 2014.
- Gilead Sciences Canada Inc. Harvoni (ledipasvir/sofosbuvir) Product Monograph. Mississauga, ON October 14, 2014.
- German P, Garrison K, Pang P, et al. Drug-drug interactions between anti-HCV regimen ledipasvir/sofosbuvir and antiretrovirals [abstract 82]. Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015, Seattle, WA.
- Bifano M, Hwang C, Oosterhuis B, et al. Assessment of HIV ARV drug interactions with the HCV NS5A replication complex inhibitor BMS-790052 demonstrates a pharmacokinetic profile which supports co-administration with tenofovir disoproxil fumarate, efavirenz, and atazanavir/ritonavir [abstract 618]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA.
- Eley T, You X, Wang R, et al. Daclatasvir: Overview of drug-drug interactions with antiretroviral agents and other common concomitant drugs [abstract]. HIV DART, December 9-12, 2014, Miami, FL.
- Menon R, Badri P, Khatri A, et al. ABT-450/ritonavir +ombitasvir + dasabuvir: drug interactions mediated by transporters. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 19-21, 2014, Washington, DC.

10. Abbvie Corporation. Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) Prescribing Information. North Chicago, IL December, 2014.
11. Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir-boosted hiv protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers [abstract 487]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC.
12. Yeh WY, Marshall W, Ma J, et al. Ritonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels [abstract 635]. Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014, Boston, MA.
13. Khatri A, Wang T, Wang H, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with HIV protease inhibitors [abstract V-484]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, 2014, Washington, DC.
14. German P, Pang P, West S, et al. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract O_06]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC.
15. Khatri A, Wang T, Wang H, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with emtricitabine + tenofovir, raltegravir, rilpivirine and efavirenz [abstract V-483]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, 2014, Washington, DC.
16. Talaty JE, Caro L, Yeh W, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and efavirenz in normal healthy volunteers [abstract 492]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November, 2013, Washington, DC.
17. Yeh W, Marshall W, Mangin E, et al. Pharmacokinetic interactions between the HCV NS5A inhibitor MK-8742 and efavirenz [abstract 498]. Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014, Boston, MA.
18. Bristol-Myers-Squibb. Daklinza (daclatasvir) Summary of Product Characteristics. European Union 2014.
19. Ouwerkerk-Mahadevan S, Sekar V, Peeters M, et al. The pharmokinetic interactions of HCV protease inhibitor TMC435 with rilpivirine, tenofovir, efavirenz or raltegravir in healthy volunteers [abstract 49]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA.
20. Taburet AM, Piroth L, Paniez H, et al. Pharmacokinetics of asunaprevir, daclatasvir and raltegravir in HCV/HIV co infected patients, with or without cirrhosis, and previously null responders to pegylated interferon + ribavirin (ANRS HC30 - QUADRIH study) [abstract 1967]. American Association for the Study of Liver Diseases The Liver Meeting (AASLD), November 7-11, 2014, Boston, MA.
21. Yeh W, Feng HP, Auger P, et al. No pharmacokinetic interaction between HCV inhibitors grazoprevir/elbasvir with rilpivirine [abstract 63]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC.
22. Garrison K, Custodio J, Pang P, et al. Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens [abstract 71]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC.
23. Song I, Jerva F, Zong J, et al. Evaluation of drug interactions between dolutegravir and daclatasvir in healthy subjects [abstract 79]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC.
24. Khatri A, Trinh R, Zhao W, et al. Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine [abstract 57]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC.

25. Yeh W, Feng HP, Guo Z, et al. Drug-drug interaction between HCV inhibitors grazoprevir/elbasvir with dolutegravir [abstract 522]. Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015, Seattle, WA.
26. Yeh W, Fraser IP, Caro L, et al. No meaningful PK interaction between HCV protease inhibitor MK-5172 and tenofovir or raltegravir [abstract 500]. 21st Conference on Retroviruses and Opportunistic Infections (CROI), Mar 3-6, 2014, Boston, MA.